A Prospective, Multicenter Comparative Case-Control Study to investigate the Clinical Efficacy of 0.1% Tacrolimus in Patients with Corneal Neovascularization

Korea University Ansan Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年12月2日

试验速览

暂无简介。

•1) Patients who visited Asan Medical Center, Yonsei University Severance Hospital, and Korea University Ansan Hospital, were diagnosed with corneal neovascularization and voluntarily agreed to participate in the clinical trial.
•2) Corneal neovascularization is diagnosed based on the following criteria.
•i. When blood vessels and opacities are observed from the limbus to the center of the cornea

•1) In case of active ocular surface inflammatory disease
•2) Those who have used Cyclosporine, steroids, or systemic immunosuppression (Glucocorticoids, Cyclophosphamide, Azathioprine, Methotrexate, etc.) within 2 weeks of the test period
•3) History of ophthalmic surgery and trauma within the last 3 months.
•- However, if LASEK/LASIK has been operated within 12 months, it is not possible to participate in the clinical trial.
•4) Those who are planning ophthalmic surgery (including LASIK/LASIK) during the study period
•5) Pregnant women, lactating women, and female patients planning to become pregnant
•6) Patients with hypersensitivity to investigational drugs
•7) Patients who are allergic to fluorescein or eye drops
•8) Contact lens wearers
•9) Others judged inappropriate by the investigator

发起方